

Disease Site Group: Blood & Marrow Transplant	
PI: Dr. Kris Paulson	A Randomized Pilot Trial comparing Anti-Thymocyte Globulin (ATG) with ATG plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT).
Disease Site Group: Brain / Central Nervous System	
PI: Dr. Marshall Pitz	A Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide vs Radiotherapy with Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low-grade Glioma
Disease Site Group: Breast	
PI: Dr. Bashir Bashir	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer.
Disease Site Group: Gastrointestinal	
PI: Dr. Christina Kim	A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
PI: Dr. Scott Hurton	Non-operative Management for Locally Advanced Rectal Cancer.
PI: Dr. Ralph Wong	A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)

Disease Site Group: Genitourinary	
PI: Dr. Bashir Bashir	A Randomized Phase III Study of Local Ablative Therapy for Hormone Sensitive Oligometastatic Prostate Cancer (Platon)
PI: Dr. Joel Gingerich	A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma that Expresses HER2.
Disease Site Group: Hematology/Hemostasis	
PI: Dr. Brett Houston	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome.
Disease Site Group: Liver	
PI: Dr. Maged Nashed	A Phase III Randomized Trial of Transarterial Chemoembolization (TACE) versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Primary or Secondary Liver Carcinoma.
Disease Site Group: Lymphoproliferative	
PI: Dr. Versha Banerji	A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
PI: Dr. Pamela Skrabek	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects \leq 70 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.

Disease Site Group: Lymphoproliferative	
PI: Dr. Leonard Minuk	A Phase I/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combo of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies
PI: Dr. Versha Banerji	Randomized, Phase II Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
PI: Dr. Pamela Skrabek	A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive BCell Lymphoma
Disease Site Group: Skin Cancer	
PI: Dr. Justin Rivard	Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.
Disease Site Group: Thoracic	
PI: Dr. James Paul	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
PI: Dr. Shantanu Banerji	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skin Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)
PI: Dr. Bashir Bashir	MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).

Disease Site Group: Thoracic	
PI: Dr. Andrew Maksymiuk	Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen
PI: Dr. Shantanu Banerji	A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Actionable Somatic Mutations Detected in Blood (BFAST).
PI: Dr. Biniam Kidane	A Phase I Study of Organ-Preserving Endoscopic Resection & Adjuvant Radio-Immuno-Chemotherapy for Esophageal Cancer (Opera Radio)
PI: Dr. James Paul	A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma